Recorded Presentation from the NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: New Options in Treatment of Relapsed/Refractory Multiple Myeloma
In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2022
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma.
Category
  • Multiple Myeloma
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
A uniform treatment approach cannot be applied to all patients with multiple myeloma (MM). Clinicians must understand when to administer two-, three- or four or more drug regimens taking into consideration disease- and patient- characteristics. Illustrating how to individualize treatment plans will help educate health care providers about how to make best decisions in their own practice and improve outcomes of patients with newly diagnosed MM.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Clinicians face a difficult task of deciding who to treat, when to treat, and how to treat especially since many factors need to considered when determining the optimal multiple myeloma (MM) treatment for relapsed/refractory MM including: age, prognostic factors, comorbidities, toxicity profiles,
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Treatment Options in Multiple Myeloma
Oncology nurses should understand the evolving therapeutic options available and the side effects related to those treatments as well as the current guidelines in the context of the patient's previous therapy and disease history to navigate the various options available.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma
Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Category
  • Multiple Myeloma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date May 20, 2022
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation